Volume 1, Issue 1 (Vaccine Research 2014)                   vacres 2014, 1(1): 25-27 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Rahimi P, Shirzadi M R, Farahtaj F, Fallahian V, Sharifian J, Howaizi N, et al . Efficacy of Purified Vero Cell Rabies Vaccine (PVRV) under the Zagreb Regimen in Iran. vacres 2014; 1 (1) :25-27
URL: http://vacres.pasteur.ac.ir/article-1-32-en.html
Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran
Abstract:   (34156 Views)

  Background: Despite the effective pre- and post-exposure treatments, at least 60,000 deaths from rabies occur worldwide every year. Post-exposure treatment is considered as one of the most significant measures for preventing human deaths in exposed individuals. The 2-1-1 rabies post-exposure treatment schedule known as Zagreb regimen is an abbreviated immunization plan in which a tissue culture rabies vaccine is administered intramuscularly at two sites on day 0 and at one site on days 7 and 21. Objectives: In this study the efficacy of rabies vaccine administration under Zagreb regimen in an Iranian group of patients attending Pasteur Institute of Iran was evaluated. Methods: Rabies neutralizing antibody titer was measured in 75 serum samples collected from 25 volunteers receiving post exposure treatment by rapid fluorescent focus inhibition test (RFFIT), and ELISA. Results: All patients were negative for rabies antibody in both ELISA and FRRIT tests on day 0 . A satisfactory rabies virus antibody response with the titer of ≥0.5 IU/ml was detected in all patients on day 21 and two weeks after the completion of vaccination (day 35). Conclusions: Rabies immunization with rabies Vero-cell vaccine (PVRV) under the 2-1-1 schedule (Zagreb regimen) could result in an adequate immune response without any adverse effect. However a more comprehensive comparative study is underway to confirm these findings . Vac Res , 2014, 1 (1): 26-28

Full-Text [PDF 418 kb]   (3092 Downloads)    
Type of Study: Original article |
Received: 2013/09/16

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 All Rights Reserved | Vaccine Research

Designed & Developed by : Yektaweb

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.